Aktieinformation KWS Saat | Filter  Basic-Info

KWS Saat

KWS Saat's core business is the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year was a good year for KWS Saat investors

Over the past year the company' stock gained around 1 percent. Over the period 2011-2016 the stock rose a massive 83,72 percent. KWS Saat's revenues between 2011 and 2015 were quite similar and moved between 986,3 million euros and 986,02 million euros. KWS Saat's net incomes between 2011 and 2015 were quiet similar and moved between 72,92 million euros and 84,05 million euros.

Over the past 5 years the German company paid out dividends. On average the KWS Saat stock yielded a delivered a dividend yield of around 13,9 percent over the past 5 years.

At the end of 2015 around 4847 thousand people were on KWS Saat' payroll.

KWS Saat financed with relatively low debt

At the end of 2015 the German company had a balance sheet of around 1,36 billion euros. The total debt of the biotech company was at the end of 2015 624,49 million euros, which equals around 46,07 percent of the total balance sheet. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio 21. So the stock' value was 21 times the 2015' earnings per share. Based on the classical stock valuation theories the German stock can be seen as a value stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 1,84 billion euros. At the end of 2015 the German company had around 6,6 million stocks listed on the stock exchange(s).

All of KWS Saat's annual reports are stored here. More information about KWS Saat can be found it's website. .